1 "Howard Boswell, Md" clinical study found.

• Phase I/II study augmenting TAK-659 action in relapsed/refractory AML by addition of the proteasome inhibitor Ixazomib Big Ten ...

  The purpose of this study is to test the safety and efficacy of combining two drugs, ixazomib and TAK-659. It ...

  Exact  Phase